Columbia University faculty present research on a previously unknown type of immune cell in kidney tumors that can predict which patients are likely to have cancer recur after surgery.

Patients with Bacillus Calmette-Guerin (BCG)-unresponsive bladder cancer remain a challenging patient population to treat. Radical cystectomy continues as the oncologic gold standard treatment in patients at high risk of recurrence after BCG failure in non-muscle-invasive bladder cancer.

Robotic-assisted radical cystectomy has assumed its rightful place in the skill set of urologic oncologists. The application of robotics to perform radical cystectomy has been steadily increasing since its introduction nearly two decades ago.

Weill Cornell Medicine has been awarded a five-year, $11.3 million Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute to improve the detection, diagnosis, and treatment of prostate cancer.

A Focus on Faculty: Highlighting a Range of Expertise

Each year, a team of specialists in the Department of Urology at NewYork-Presbyterian/Columbia University Medical Center diagnoses and treats more than 6,000 patients with urinary disorders.

The advent of robotically assisted and minimally invasive surgical practices, along with newer imaging approaches, has dramatically transformed treatment options for patients with prostate cancer.

As one of the country’s leading experts in adult reconstructive urology, Steven B. Brandes, MD, cares for patients with the most complex conditions and disorders of the genitourinary system.